NCT07737509 Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample Analysis
| NCT ID | NCT07737509 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Cancer Research, United Kingdom |
| Condition | Advanced Solid Tumours |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2021-04-28 |
| Primary Completion | 2036-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2021-04-28 with a primary completion date of 2036-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to attempt to find altered genetic 'switches' (mutations) in adults with advanced solid cancers who are being considered for, or are participating in, early-phase cancer clinical trials. Research has shown that cancer cells make use of key mutations to 'switch on' their growth, spread, and survival. This study will use this information to evaluate what happens to mutations over time which may help match patients to suitable clinical trials and support the development of more personalised cancer treatments. The main question it aims to answer is: Can mutations identified in various samples, including tumour samples and blood samples, help predict which patients are most likely to benefit from specific cancer treatments or clinical trials? Participants will provide consent to allow previously collected tumour samples, such as tissue from earlier biopsies or surgery, to be used for molecular analysis; allow researchers to collect and analyse clinical information about their cancer, treatments, clinical trial participation, and outcomes; be asked to provide optional research samples, which may include blood, urine, saliva, stool samples, cheek swabs, rectal swabs, tumour biopsies, and other bodily fluids when clinically appropriate; have tumour and other samples analysed to identify genetic and molecular changes that may influence cancer growth, treatment response, and treatment resistance; be informed if clinically significant findings are identified that may be relevant to their cancer care; and be followed over time through review of medical records to monitor clinical outcomes and the safety of research sample collection procedures, including biopsies. This study does not test a specific treatment. Information gained from the study may help researchers better understand cancer biology, identify new treatment targets, improve patient selection for future clinical trials, and support the development of personalised cancer therapies.
Eligibility Criteria
Inclusion Criteria: 1. Histologically, cytologically or biochemically confirmed diagnosis of advanced solid cancer 2. Older than or equal to 18 years of age 3. Patients who are being considered for an early phase clinical trial or who are currently participating in an early phase clinical trial 4. Written (signed and dated) informed consent. Exclusion Criteria: N/A.
Contact & Investigator
Professor Johann de Bono
STUDY DIRECTOR
Institute of Cancer Research, United Kingdom
Frequently Asked Questions
Who can join the NCT07737509 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Solid Tumours. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07737509 currently recruiting?
Yes, NCT07737509 is actively recruiting participants. Contact the research team at MC2@icr.ac.uk for enrollment information.
Where is the NCT07737509 trial being conducted?
This trial is being conducted at Sutton, United Kingdom, Sutton, United Kingdom.
Who is sponsoring the NCT07737509 clinical trial?
NCT07737509 is sponsored by Institute of Cancer Research, United Kingdom. The principal investigator is Professor Johann de Bono at Institute of Cancer Research, United Kingdom. The trial plans to enroll 5,000 participants.